Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 401–500 of 1,000
Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 72
Wei, H., Xu, Y., Wang, Y., Xu, L., Mo, C., Li, L., Shen, B., Sun, Y., Cheng, P., Yang, L., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108252 · Cited by 72
Koustoulidou, S., Hoorens, M. W. H., Dalm, S. U., Mahajan, S., Debets, R., Seimbille, Y., & de Jong, M. (2021) · Cancers · doi:10.3390/cancers13051100 · Cited by 73
Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma
Ray, A., Callaway, M. K., Rodríguez-Merced, N. J., Crampton, A. L., Carlson, M., Emme, K. B., Ensminger, E. A., Kinne, A. A., Schrope, J. H., Rasmussen, H. R., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.150330 · Cited by 69
Chen, M., Xiang, R., Wen, Y., Xu, G., Wang, C., Luo, S., Yin, T., Wei, X., Shao, B., Liu, N., et al. (2015) · Scientific Reports · doi:10.1038/srep14421 · Cited by 63
Érsek, B., Silló, P., Çakır, U., Molnár, V., Bencsik, A., Mayer, B., Mezey, É., Kárpáti, S., Pós, Z., & Németh, K. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03517-8 · Cited by 70
Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
Ria, R., & Vacca, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020613 · Cited by 71
Das, S., Valton, J., Duchateau, P. N., & Poirot, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172681 · Cited by 69
“Together, these physical and chemical barriers foster T-cell exclusion and exhaustion (13, 14).”
BackgroundAnstee, J. E., Feehan, K. T., Opzoomer, J. W., Dean, I., Muller, H. P., Bahri, M., Cheung, T. S., Liakath‐Ali, K., Liu, Z., Choy, D., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2023.06.006 · Cited by 70
Self-citationThe fibroinflammatory response in cancer
Xiao, Z., & Puré, E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00798-8 · Cited by 74
Scarlett, C. J., Colvin, E. K., Pinese, M., Chang, D. K., Morey, A. L., Musgrove, E. A., Pajic, M., Apte, M., Henshall, S. M., Sutherland, R. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026088 · Cited by 67
Mezheyeuski, A., Segersten, U., Leiss, L. W., Malmström, P., Hatina, J., Östman, A., & Strell, C. (2020) · Scientific Reports · doi:10.1038/s41598-019-55013-0 · Cited by 71
Li, B., Zu, M., Jiang, A., Cao, Y., Wu, J., Shahbazi, M.-A., Shi, X., Reis, R. L., Kundu, S. C., & Xiao, B. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122530 · Cited by 67
Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas
Kerkar, S. P., Leonardi, A. J., van Panhuys, N., Zhang, L., Yu, Z., Crompton, J. G., Pan, J. H., Palmer, D. C., Morgan, R. A., Rosenberg, S. A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.58 · Cited by 64
Sugrue, T., Brown, J. A. L., Lowndes, N. F., & Ceredig, R. (2012) · Stem Cells · doi:10.1002/stem.1222 · Cited by 67
Muliaditan, T., Opzoomer, J. W., Caron, J., Okesola, M., Kosti, P., Lall, S. K., Hemelrijck, M. V., Dazzi, F., Tutt, A. N. J., Grigoriadis, A. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2587 · Cited by 70
Self-citationLim, E. L., Cugliandolo, F. M., Rosner, D. R., Gyori, D., Roychoudhuri, R., & Okkenhaug, K. (2018) · JCI Insight · doi:10.1172/jci.insight.120626 · Cited by 66
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 66
“The removal of FAP-positive CAFs was shown to reactivate the anti-tumor activity of immune cells of T cells (Kraman et al., 2010).”
FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung Cancer
Wei, Y., Ma, L., Li, P. Z., Lu, J., Ren, J., Yan, S., Wu, H., Yuan, S., Fu, Z., & Yu, J. (2023) · Radiology · doi:10.1148/radiol.222785 · Cited by 66
Kim, H. M., Jung, W. H., & Koo, J. S. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0587-9 · Cited by 71
“Various proteins have been suggested as markers for CAF, including α-SMA [11], tenascin-C [12], chondroitin sulfate proteoglycan (NG2) [13], platelet-derived growth factor receptors (PDGFR)α/β [14], fibroblast activation protein (FAP) [15], podoplanin [16], prolyl 4-hydroxylase [17], and fibroblast-specific protein (F…”
BackgroundDPPIV/CD26: a tumor suppressor or a marker of malignancy?
Beckenkamp, A., Davies, S., Willig, J. B., & Buffon, A. (2016) · Tumor Biology · doi:10.1007/s13277-016-5005-2 · Cited by 66
A real-time fluorometric method for the simultaneous detection of cell death type and rate
Grootjans, S., Hassannia, B., Delrue, I., Goossens, V., Wiernicki, B., Dondelinger, Y., Bertrand, M. J. M., Krysko, D. V., Vuylsteke, M., Vandenabeele, P., et al. (2016) · Nature Protocols · doi:10.1038/nprot.2016.085 · Cited by 71
Juillerat‐Jeanneret, L., Tafelmeyer, P., & Golshayan, D. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1370455 · Cited by 71
“FAP-α has been involved in cancer progression by interfering with the functions of the cancer microenvironment, the cancer stroma [74,83,113,114,119-122].”
Dysregulation of key microRNAs in pancreatic cancer development
Baradaran, B., Shahbazi, R., & Khordadmehr, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.177 · Cited by 70
Chen, H., Zhang, Y., Wu, C., & Huang, Q. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01428-8 · Cited by 71
Gunaydin, G., Kesikli, S. A., & Guc, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1034918 · Cited by 59
“proposed a population of fibroblast activation protein-a (FAP-a) expressing cells to be an immunosuppressive component of the tumor microenvironment.(37) Accordingly, fibroblasts at the tumor site were analyzed to find out whether they exhibit similar immunosuppressive characteristics like their circulating counterpar…”
BackgroundTargeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer
Tchou, J. C., & Conejo-Garcia, J. R. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00003-8 · Cited by 64
Tang, D., Gao, J., Wang, S., Yuan, Z., Ye, N., Chong, Y., Xu, C., Jiang, X., Li, B., Yin, W., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3233-5 · Cited by 64
“immune cells and/or their function inside tumors, in part via secretion of immunosuppressive cytokines, and consequently promotes the immune escape of tumor cells [7, 8].”
BackgroundSiegert, S., & Luther, S. A. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00285 · Cited by 71
Kadel, D., Zhang, Y., Sun, H.-R., Zhao, Y., Dong, Q.-Z., & Qin, L.-X. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09461-z · Cited by 63
“The role of fibroblast in altering the immune-controlled tumor growth was described in transgenic Lewis lung carcinoma and subcutaneous PDAC mouse model, where it was observed that depletion of FAP-expressing cells enhanced the hypoxic necrosis of both tumor and stromal cells by a process involving interferon-γ (IFN-γ…”
BackgroundOsman, A., Afify, S. M., Hassan, G., Fu, X., Seno, A., & Seno, M. (2020) · Cancers · doi:10.3390/cancers12040879 · Cited by 63
“Abbreviations Abbreviations Full Names ATRA all-trans retinoic acid BM bone marrow CAFs cancer-associated fibroblasts CSCs cancer stem cells ECM extracellular matrix; ECs: endothelial cells EMT epithelial mesenchymal transition FAP-α fibroblast activation protein-α FGF-2 fibroblast growth factor FGFs fibroblast growth…”
BackgroundTargeting roles of inflammatory microenvironment in lung cancer and metastasis
Shi, L., Wang, L., Hou, J., Zhu, B., Min, Z., Zhang, M., Song, D., Cheng, Y., & Wang, X. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9570-4 · Cited by 62
Lee, Y. E., Go, G.-Y., Koh, E.-Y., Yoon, H.-N., Seo, M., Hong, S.-M., Jeong, J. H., Kim, J.-C., Cho, D., Kim, T. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006130 · Cited by 61
Wei, R., Song, J., Liu, C., Zhao, Z., Liu, X., Yamamoto, M., Tsukamoto, T., Nomura, S., Liu, F., Wang, Y., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217475 · Cited by 64
CAR T‐cell immunotherapy: The path from the by‐road to the freeway?
Whilding, L. M., & Maher, J. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.012 · Cited by 64
“Selective ablation of FAPþ CAFs in transgenic mice allows immunological control of PDAC tumour growth (Kraman et al., 2010), suggesting that targeting of these cells could also augment CAR T-cell therapy.”
BackgroundPlasma Seprase and DPP4 Levels as Markers of Disease and Prognosis in Cancer
Javidroozi, M., Zucker, S., & Chen, W. (2012) · Disease Markers · doi:10.1155/2012/706745 · Cited by 61
PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
Mucileanu, A., Chira, R. I., & Mircea, P. A. (2021) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2116 · Cited by 61
Chesler, L., & Weiss, W. A. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.011 · Cited by 68
“It is becoming apparent that in certain trial designs, GEMM may provide superior modeling of drug response as compared to exogenous implantation models [154,155].”
BackgroundGottschalk, S. M., Feng, Y., Ji, M., Kakarla, S., & Song, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082658 · Cited by 61
Ryabtsova, O. V., Jansen, K., Goethem, S. V., Joossens, J., Cheng, J. D., Lambeir, A., Meester, I. D., Augustyns, K., & der Veken, P. V. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.107 · Cited by 60
Embryonic FAP+ lymphoid tissue organizer cells generate the reticular network of adult lymph nodes
Denton, A. E., Carr, E. J., Magiera, Ł., Watts, A. J. B., & Fearon, D. T. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181705 · Cited by 61
“Tg(FaptTA) BAC transgenic mice were generated as described (Kraman et al., 2010; Roberts et al., 2013).”
MethodSelf-citationLi, M., Li, G., Kiyokawa, J., Tirmizi, Z. A., Richardson, L. G., Ning, J., Das, S., Martuza, R. L., Stemmer-Rachamimov, A. O., Rabkin, S. D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01096-0 · Cited by 60
Mesenchymal stem cells inhibit T-cell function through conserved induction of cellular stress
Laing, A. G., Fanelli, G., Ramirez-Valdez, A., Lechler, R. I., Lombardi, G., & Sharpe, P. T. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213170 · Cited by 59
Role of Serine Proteases at the Tumor-Stroma Interface
Tagirasa, R., & Yoo, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832418 · Cited by 62
“When FAP cells were depleted in lung or pancreatic cancers, it caused immediate growth arrest of immunogenic tumor through TNF-a- and IFN-g-mediated mechanism (38).”
BackgroundLoss of Fibroblast HIF-1α Accelerates Tumorigenesis
Kim, J.-W., Evans, C., Weidemann, A., Takeda, N., Lee, Y. S., Stockmann, C., Branco-Price, C., Brandberg, F., Leone, G., Ostrowski, M. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0534 · Cited by 57
Vernon, P. J., Loux, T. J., Schapiro, N. E., Kang, R., Muthuswamy, R., Kalinski, P., Tang, D., Lotze, M. T., & Zeh, H. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201151 · Cited by 57
Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer
Salimifard, S., Masjedi, A., Hojjat‐Farsangi, M., Ghalamfarsa, G., Irandoust, M., Azizi, G., Mohammadi, H., Keramati, M. R., & Jadidi‐Niaragh, F. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152915 · Cited by 60
Extracellular Vesicles Are Key Regulators of Tumor Neovasculature
Kuriyama, N., Yoshioka, Y., Kikuchi, S., Azuma, N., & Ochiya, T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.611039 · Cited by 60
“Myofibroblasts are one of the main subtypes of CAFs that express α-smooth muscle actin (α-SMA) (Sappino et al., 1988; Kraman et al., 2010).”
BackgroundMesenchymal stromal cells: radio‐resistant members of the bone marrow
Sugrue, T., Lowndes, N. F., & Ceredig, R. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.61 · Cited by 58
Kilvaer, T. K., Rakaee, M., Hellevik, T., Østman, A., Strell, C., Bremnes, R. M., Busund, L.-T., Dønnem, T., & Martinez-Zubiaurre, I. (2018) · PLOS ONE · doi:10.1371/journal.pone.0192157 · Cited by 57
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
Fight the Cancer, Hit the CAF!
Papait, A., Romoli, J., Stefani, F. R., Chiodelli, P., Montresor, M. C., Agoni, L., Silini, A. R., & Parolini, O. (2022) · Cancers · doi:10.3390/cancers14153570 · Cited by 60
The role of tumor microenvironment on cancer stem cell fate in solid tumors
Razi, S., Haghparast, A., Khameneh, S. C., Sadrabadi, A. E., Aziziyan, F., Bakhtiyari, M., Nabi‐Afjadi, M., Tarhriz, V., Jalili, A., & Zalpoor, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01129-w · Cited by 59
Sunami, Y., Boeker, V., & Kleeff, J. H. (2021) · Cancers · doi:10.3390/cancers13040697 · Cited by 58
Sitia, L., Bonizzi, A., Mazzucchelli, S., Negri, S., Sottani, C., Grignani, E., Rizzuto, M. A., Prosperi, D., Sorrentino, L., Morasso, C., et al. (2021) · Cells · doi:10.3390/cells10020328 · Cited by 57
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
Deng, D., Patel, R. H., Chiang, C.-Y., & Hou, P. (2022) · Cells · doi:10.3390/cells11192952 · Cited by 60
Fibroblasts as Turned Agents in Cancer Progression
Wieder, R. (2023) · Cancers · doi:10.3390/cancers15072014 · Cited by 57
Carlo, S. E. D., Raffenne, J., Varet, H., Ode, A., Granados, D. C., Stein, M., Legendre, R., Tuckermann, J. P., Bousquet, C., & Peduto, L. (2023) · Nature Immunology · doi:10.1038/s41590-023-01642-7 · Cited by 56
Wang, H., Liu, F., Wu, X., Zhu, G., Tang, Z., Qu, W., Zhao, Q., Huang, R., Tian, M., Fang, Y., et al. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.113947 · Cited by 56
Lu, X., Gou, Z., Chen, H., Li, L., Chen, F., Bao, C., Bu, H., & Zhang, Z. (2025) · The Journal of Pathology · doi:10.1002/path.6395 · Cited by 59
Michl, P., & Gress, T. M. (2012) · Gut · doi:10.1136/gutjnl-2012-302604 · Cited by 59
Zhang, W., Liu, Q., Wu, J., Xu, B., Wang, J., Liang, L., Guo, Y., Peng, M., Zhao, Y., & Liao, Q. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.164 · Cited by 56
“FAPα has also been associated with growth, invasion, metastasis, and angiogenesis in epithelialderived malignancies (16,25,26).”
BackgroundTorphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 62
Hanley, C. J., Henriet, E., Sirka, O. K., Thomas, G. J., & Ewald, A. J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0334 · Cited by 56
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Jenkins, B. H., Buckingham, J. F., Hanley, C. J., & Thomas, G. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108231 · Cited by 57
Walsh, M. P., Duncan, B. B., Larabee, S. M., Krauss, A. C., Davis, J. P. E., Cui, Y., Kim, S. Y., Guimond, M., Bachovchin, W. W., & Fry, T. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058860 · Cited by 56
Ansardamavandi, A., & Tafazzoli‐Shadpour, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119103 · Cited by 57
Shintani, Y., Kimura, T., Funaki, S., Ose, N., Kanou, T., & Fukui, E. (2023) · Cancers · doi:10.3390/cancers15020335 · Cited by 57
“A transgenic mouse in which FAP-expressing cells can be ablated showed decreases in both ECM production and T-cell retention in the stroma of Lewis lung carcinomas by a process involving IFNγ and tumor necrosis factor-α [91].”
BackgroundWang, Z., Wang, J., Lan, T., Zhang, L., Yan, Z., Zhang, N., Xu, Y., & Tao, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135384 · Cited by 62
“Meanwhile, some studies have also indicated that FAP has immunosuppressive effects, and that CD4/CD8 T cell activity is increased after removing FAP cells in mice (119).”
BackgroundBispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma
Zhou, L., Li, Y., Zheng, D., Zheng, Y., Cui, Y., Qin, L., Tang, Z., Peng, D., Wu, Q., Long, Y., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200817 · Cited by 63
Sakai, T., Aokage, K., Neri, S., Nakamura, H., Nomura, S., Tane, K., Miyoshi, T., Sugano, M., Kojima, M., Fujii, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.021 · Cited by 57
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
Harryvan, T. J., Verdegaal, E. M. E., Hardwick, J. C. H., Hawinkels, L. J. A. C., & van der Burg, S. H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111989 · Cited by 57
Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells
Arina, A., & Bronte, V. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.006 · Cited by 55
Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises
Mei, L., Du, W., & Ma, W. W. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.03.03 · Cited by 56
Lü, L., Gao, Y., Huang, D., Liu, H., Yin, D., Li, M., Zheng, J., Wang, S., Wu, W., Zhao, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007447 · Cited by 55
Christiansen, V. J., Jackson, K. W., Lee, K. N., Downs, T., & McKee, P. A. (2013) · Neoplasia · doi:10.1593/neo.121850 · Cited by 61
“[45] Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO,”
BackgroundFibroblasts, an inconspicuous but essential player in colon cancer development and progression
Mukaida, N., & Sasaki, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i23.5301 · Cited by 54
A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma
Yang, H., Zhao, L., Zhang, Y., & Li, F. (2021) · Cancer Medicine · doi:10.1002/cam4.4117 · Cited by 53
Xu, Y., Li, W., Lin, S., Liu, B., Wu, P., & Li, L. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01204-2 · Cited by 55
Lu, Y., Chen, Y., Wang, Z., Shen, H., Xu, L., Huang, C., Tong, Y., Shao, Y., Zhang, H., & Fu, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06236-5 · Cited by 56
Li, Y., Wang, L., Ma, W., Wu, J., Wu, Q., & Sun, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06744-4 · Cited by 58
Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor
Kim, T. S., Cavnar, M. J., Cohen, N. A., Sorenson, E. C., Greer, J. B., Seifert, A. M., Crawley, M. H., Green, B. L., Popow, R., Pillarsetty, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3033 · Cited by 52
Epithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & Pasca di Magliano, M. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 49
A purine metabolic checkpoint that prevents autoimmunity and autoinflammation
Saveljeva, S., Sewell, G. W., Ramshorn, K., Cader, M. Z., West, J. A., Clare, S., Haag, L.-M., Rodrigues, R. P. D. A., Unger, L. W., Iglesias-Romero, A. B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.009 · Cited by 57
“5, CAS: 2483736-24-7 Sodium chloride Sigma-Aldrich Cat# S9888, CAS 7647-14-5 Sodium pyruvate Sigma-Aldrich Cat# P5280, CAS 113-24-6 Sodium pyruvate-13C3 Sigma-Aldrich Cat# 490717, CAS 142014-11-7 SYTOX Blue Dead Cell Stain Thermo Fisher Scientific Cat# S34857 SYTOX Green Nucleic Acid Stain Thermo Fisher Scientific Cat…”
BackgroundInfluentialSelf-citationTumor-stromal interactions in pancreatic cancer
Tod, J., Jenei, V., Thomas, G. J., & Fine, D. R. (2013) · Pancreatology · doi:10.1016/j.pan.2012.11.311 · Cited by 53
Heat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity
Calderwood, S. K., Murshid, A., & Gong, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00075 · Cited by 55
“The tumor milieu also contain a small fraction of cells of mesenchymal origin identified by surface fibroblast activation protein-a (FAP cells) that suppress antitumor immune responses (Kraman et al., 2010).”
BackgroundImmunotherapy: Beyond Anti–PD-1 and Anti–PD-L1 Therapies
Antonia, S. J., Vansteenkiste, J. F., & Moon, E. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158712 · Cited by 48
Improving homing in T cell therapy
Vignali, D., & Kallikourdis, M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.009 · Cited by 54
Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding
Guo, H., Tsai, C.-L., Terajima, M., Tan, X., Banerjee, P., Miller, M. D., Liu, X., Jiang, Y. L., Byemerwa, J. K., Alvarado, S. K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02859-z · Cited by 52
Immunotherapy of pancreatic cancer
Sunami, Y., & Kleeff, J. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.006 · Cited by 57
A bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective
Pradhan, R., Krishnamurty, A. T., Fletcher, A. L., Turley, S. J., & Müller, S. (2021) · Immunological Reviews · doi:10.1111/imr.12990 · Cited by 53
Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance
Willimsky, G., Schmidt, K., Loddenkemper, C., Gellermann, J., & Blankenstein, T. J. F. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64742 · Cited by 54
FRET‐based and other fluorescent proteinase probes
Hu, H., Gehrig, S. M., Reither, G., Subramanian, D., Mall, M. A., Plettenburg, O., & Schultz, C. (2014) · Biotechnology Journal · doi:10.1002/biot.201300201 · Cited by 55
“In engineered mice, elimination of FAP-producing stromal cells allowed the immune system to control the growth of malignant tumors [155].”
BackgroundStromal Cells Present in the Melanoma Niche Affect Tumor Invasiveness and Its Resistance to Therapy
Mazurkiewicz, J., Simiczyjew, A., Dratkiewicz, E., Ziętek, M., Matkowski, R., & Nowak, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020529 · Cited by 53
“FAP is also thought to suppress T cell recruitment and function and, therefore, support melanoma immune escape [96,97].”
BackgroundIrvine, A. F., Waise, S., Green, E. W., Stuart, B. L., & Thomas, G. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-81796-2 · Cited by 55
Yuan, Z., Hu, H., Zhu, Y., Zhang, W., Fang, Q., Qiao, T., Ma, T., Wang, M., Huang, R., Tang, Q., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03823-4 · Cited by 51
Targeting stromal cell Syndecan‐2 reduces breast tumour growth, metastasis and limits immune evasion
Loftus, P., Watson, L., Deedigan, L., Camarillo‐Retamosa, E., Dwyer, R. M., O’Flynn, L., Alagesan, S., Griffin, M. D., O’Brien, T., Kerin, M. J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33383 · Cited by 50
“However, F IGURE 5 Syndecan-2 peptide reduces the immunosuppressive properties of TASCs, reduces tumour growth and increases the percentage of activated T cells within the TME.”
BackgroundInfluentialMirhadi, S., Tam, S., Li, Q., Moghal, N., Pham, N., Tong, J., Golbourn, B. J., Krieger, J. R., Taylor, P. P., Li, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29444-9 · Cited by 58
Hak, C. C. W., Rullan, A., Patin, E. C., Pedersen, M., Melcher, A. A., & Harrington, K. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.971959 · Cited by 51
Hypoxia Enhances the Radioresistance of Mouse Mesenchymal Stromal Cells
Sugrue, T., Lowndes, N. F., & Ceredig, R. (2014) · Stem Cells · doi:10.1002/stem.1683 · Cited by 50
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.